Monday, October 3, 2022


Biotechnology News Magazine

VarMap Pan-Cancer NGS Panel Launches Reports NuProbe

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

February 22, 2021

VarMap Pan-Cancer NGS Panel uses the quantitative blocker displacement amplification (QBDA) technology to enrich, detect, and quantitate over 6500 mutations and indels in 61 clinically relevant genes.

The panel can be used on cfDNA samples to detect mutations down to 0.1% variant allele frequency (VAF) using only 1 million NGS reads. The panel can also be applied to FFPE tumor samples or other cellular samples for minimum residual disease (MRD) detection, detecting mutations down to 0.01% VAF.

“The QBDA technology reduces the NGS sequencing depth needed for rare mutation detection by a factor of 100,” said David Zhang, Ph.D., Co-founder and Head of Innovation of NuProbe, and Associate Professor of Bioengineering at Rice University. “This allows the VarMapTM Pan-Cancer NGS Panel to accurately analyze cfDNA mutations using only 1 million reads per sample, enabling liquid biopsy analysis on instruments like the MiSeq and MiniSeq.  Simultaneously, by increasing to sequencing to 20 million reads per sample, the panel is able to detect single-base mutations down to 0.01% VAF, enabling more sensitive detection of MRD.”

“In diseases like acute myeloid leukemia (AML), MRD is detectable with extremely high sensitivity for patients with specific gene fusions.  However, most AML patients do not have common gene fusions, and MRD detection is much more challenging for such patients because point mutations are difficult to detect at very low variant allele fractions,” said Abhijit Patel, a member of NuProbe’s Scientific Advisory Board.  “By delivering 0.01% VAF sensitivity to point mutations, the VarMapTM Pan-Cancer NGS Panel is poised to significantly improve the clinical sensitivity of MRD detection for diseases such as AML.”

The VarMap Pan-Cancer NGS Panel covers hotspot regions of 61 oncogenes and tumor suppressor genes most recurrent mutated across a wide variety of cancer types.  Over 6500 mutations and indels listed in the COSMIC, TCGA, and OncoKB databases are covered by the panel.  Recommended sample requirements for the VarMapTM Pan-Cancer NGS Panel are 20ng of cfDNA or 50ng of FFPE DNA for standard operation.

For MRD, 1 µg of gDNA is recommended for detection down to 0.01% VAF.  Bioinformatic software for interpreting results and making quantitative variant calls are included.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine